HGFK1 Inhibits Bone Metastasis in Breast Cancer Through the TAK1/p38 MAPK Signaling Pathway

Y-Z. Bu,Z. Shen
DOI: https://doi.org/10.1016/s0923-7534(20)32910-0
IF: 51.769
2012-01-01
Annals of Oncology
Abstract:ABSTRACT Background Breast cancer metastasis to bone represents a devastating complication of advanced breast cancer, frequently resulting in significant increases in morbidity and mortality. An understanding of the mechanisms that govern breast cancer metastasis at the molecular level should lead to more effective therapies. Recently, the kringle 1 domain of human hepatocyte growth factor (HGFK1) was identified as a candidate metastasis suppressor gene. Methods Here, we investigated whether HGFK1 is a key regulator of breast cancer bone metastasis. Results Of the 193 human breast carcinoma tissue samples examined, HGFK1 expression was positive in 82 (42.4%). The positive expression of HGFK1 was significantly associated with a better prognostic value (P Conclusions This study shows for the first time that HGFK1 significantly inhibits the metastasis of breast cancer to bone by activating the TAK1/p38 MAPK signaling pathway and inhibiting RANK expression. Thus, AAV-HGFK1 treatment represents a potential therapy for bone metastasis in breast cancer. Disclosure All authors have declared no conflicts of interest.
What problem does this paper attempt to address?